Advocates demand Cepheid commit a greater proportion of its COVID-19 manufacturing capacity to LMICs and lower the price of its cartridges to $5.

Available in English, Arabic, French, Portuguese, Russian and Spanish.

On International Women’s Day, 8 March 2021, TBWomen will be launched as a network accompanied by a short panel discussion featuring women who lead in TB. TBWomen is a new global network of women in their diversity working toward a gender-transformative TB response. The event will be co-hosted by the Stop TB Partnership which will release a position paper focusing on gender-sensitive TB interventions.

Developing reasonably priced, easy-to-use diagnosis kits that can swiftly and accurately detect infectious diseases in developing countries has become the main mission of Chie Nakajima and Kyoko Hayashida, as they seek to alleviate some of the hardship endured by poverty-stricken people.

As Covid-19 impacts lives around the world, a new skeleton study is reconstructing ancient pandemics to assess human's evolutionary ability to fight off leprosy, tuberculosis and treponematoses with help from declining rates of transmission when the germs became widespread.

To mark International Women’s Day, the World Health Organization and the Global Coalition of TB Activists will host a webinar on 8 March 2021, #ChooseToChallenge: A Gender-Sensitive & Equitable Response to End TB. It will explore barriers and will envisage solutions for seeking equitable health care for women and gender inclusivity in the global response to end TB.

Tuberculosis bacteria have evolved to remember stressful encounters and react quickly to future stress, according to a study by computational bioengineers at Rice University and infectious disease experts at Rutgers New Jersey Medical School (NJMS).

The treatment of tuberculosis (TB) is long, demanding, and expensive. In particular, the ever increasing emergence of resistant tuberculosis bacteria requires a lot of patience: In these cases, the WHO generally recommends a standard treatment duration of at least 18 months, as there are no reliable biomarkers for an early termination. Under the leadership of the DZIF scientists at the Research Center Borstel, six years of research have now succeeded in identifying a biomarker that points to an individual end of therapy based on the activity of 22 genes. In many cases, this probably allows the treatment to be shortened safely.

A comment published in The Lancet Child & Adolescent Health addressed the issue of the provision of TB preventive therapy for all forms of TB as an emergency measure to combat the devastating effect of COVID-19 on TB not only by averting the development of active TB disease and the ensuing morbidity and mortality in the paediatric population but also by easing the strain of overstretched health-care systems.

Indian activists demand the introduction of the newer short-course TB preventive treatment regimens for people living with HIV.